DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO DECLARE FOR USE IN THE INFORMATION EXCHANGE

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2 (i)		
A, part 2 (ii)		
A, part 2 (iii)		
B (I)		
B (ii)	x	
C		
D		
E		x
F	x	
G		x

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 2010

State Party to the Convention: Finland

CONFEDENCE-BUILDING MEASURE A

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#1

1. **Name(s) of the Facility**
   Centre for Biothreat Preparedness

2. **Responsible public or private organization or company**
   Centre for Military Medicine, Finnish Defence Forces under the Ministry of Defence and the National Institute for Health and Welfare (THL) under Ministry of Social Affairs and Health.

3. **Location and postal address**
   Tukholmankatu 8 A, FI-00290 Helsinki and Mannerheimintie 166, FI-00300 Helsinki.

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The Centre is financed jointly by the Finnish Defence Forces and National Institute for Health and Welfare (THL)

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   There are no BSL-4 units at the Centre.

6. **If no maximum containment unit, indicate highest level of protection**
   BSL-3, 120m^2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The Centre for Biothreat Preparedness started its activities in 2005. During 2009, the Centre developed rapid PCR detection assays for selected microbial agents.

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#2

1. **Name(s) of the Facility**
   National Institute for Health and Welfare (THL)*, Bacteriological and Virological laboratories

2. **Responsible public or private organization or company**
   National Institute for Health and Welfare (THL)* under Ministry of Social Affairs and Health

3. **Location and postal address**
   Mannerheimintie 166
   FI-00300 Helsinki

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Funding from the Ministry of Social Affairs and Health and large variety of external research funding.

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   There are no BSL-4 laboratories or other units at this containment level.

6. **If no maximum containment unit, indicate highest level of protection**
   Three BSL-3 level laboratories. 120m^2 and 20m^2 in Helsinki, 80m^2 in Turku.

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Clinical and environmental microbiological research and reference laboratory facilities in Helsinki, Turku, Kuopio and Oulu. Work mainly with ordinary occurring endemic and epidemic bacteria and viruses with main emphases on vaccine preventable diseases, enteric pathogens, zoonoses, tuberculosis spp, enteroviruses, polioviruses, influenza (including pandemic H1N1v), HIV, hepatitis viruses and environmental fungi and bacteria causing human health problems. The Institute manages regional Influenza and Polio laboratory facilities. The Institute is in charge of biothreat preparedness in public health context. National focal point for IHR started June 2007.

*The National Public Health Institute (KTL) and the National Research and Development Centre for Welfare and Health (STAKES) joined forces to form the National Institute for Health and Welfare (THL) on 1 January 2009.

Exchange of Data on Research Centres and Laboratories -#3

1. **Name(s) of the Facility**
   Yersinia Research Laboratory

2. **Responsible public or private organization or company**
   University of Helsinki
   University of Turku

3. **Location and postal address**
   Department of Bacteriology and Immunology
   Haartman Institute, University of Helsinki
   Haartmaninkatu 3
   P.O Box 21
   FI-00014 University of Helsinki
   Helsinki, Finland

   and
   Department of Medical Biochemistry and Genetics
   University of Turku
   Kiinamyllynkatu 10
   FI-20520 Turku, Finland

   Yersinia-research home page: Http://www.hi.helsinki.fi/yersinia/

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Academy of Finland, Centre of Military Medicine

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   No BSL-4 laboratories.

6. **If no maximum containment unit, indicate highest level of protection**
   Containment level BSL-2. The studied microbes have been attenuated or are avirulent.

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The research is focused on genetics and biosynthesis of lipopolysaccharide (LPS) of *Yersinia pestis*, as well as on the role of LPS in virulence. Molecular evolution studies elucidate the relationships between the species of the genus *Yersinia.* Research work is also conducted on the identification of *Y. pestis* specific bacteriophage receptors.

Exchange of Data on Research Centres and Laboratories -#4

1. **Name(s) of the research centre and/or laboratory**
   Department of Virology

2. **Responsible public or private organization or company**
   University of Helsinki

3. **Location and postal address**
   P.O. Box 21
   Haartman Institute
   00014 University of Helsinki

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   In 2009: Funding from Helsinki University Hospital EVO-fund, University of Helsinki, National Technology Agency of Finland, Academy of Finland, Sigrid Jusélius Foundation, European Union and University of Helsinki Funds. A project on alphavirus and flavivirus RNA detection funded by the Centre for Military Medicine has started.

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   There are no BSL-4 laboratories.

6. **If no maximum containment unit, indicate highest level of protection**
   BSL-3, 75 m^2 (at Meilahti campus) and 100 m^2 (at Viikki campus)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The Helsinki University Viral Zoonoses Group (HUVZG) conducts research on virology, cell biology, ecology and epidemiology of zoonotic viruses, especially hantaviruses and certain other rodent-borne and arboviruses occurring in Northern Europe. Our research group operates within Faculty of Medicine, Haartman Institute Department of Virology, and partially at the Division of Microbiology and Immunology at the Veterinary Faculty, has a BSL-3 facility in both faculties, is connected to diagnostic laboratory of viral zoonoses in HUSLAB, Helsinki, and also acts as a WHO Collaborating Centre for Arbo- and Zoonotic Viruses. Principal investigators of the group are Alexander Plyusnin, Antti Vaheri and Olli Vapalahti.

Exchange of Data on Research Centres and Laboratories -#5

1. **Name(s) of the Facility**
   Finnish Food Safety Authority (Evira)

2. **Responsible public or private organization or company**
   Finnish Food Safety Authority under the Ministry of Agriculture and Forestry

3. **Location and postal address**
   Mustialankatu 3
   FI-00790 Helsinki

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Financing from the Ministry of Agriculture and Forestry

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   None

6. **If no maximum containment unit, indicate highest level of protection**
   Six containment level 3+ laboratories, total size 473,5m^2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Diagnostics of animal diseases, for example rabies, avian influenza, swine influenza (including pandemic H1N1 in pigs), Newcastle disease, foot and mouth disease, classical swine fever, anthrax, tuberculosis, verotoxic *E. coli.*

Form A, part 1

Exchange of Data on Research Centres and Laboratories -#6

1. **Name(s) of the Facility**
   Finnish Defence Forces Technical Research Centre (PVTT)

2. **Responsible public or private organization or company**
   Finnish Defence Forces Technical Research Centre (PVTT), Finnish Defence Forces under the Defence Staff

3. **Location and postal address**
   P.O. Box 5 (Paroistentie 20)
   FI-34111 Lakiala
   Finland

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Finnish Defence Forces

5. **Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
   No BSL-4 laboratories.

6. **If no maximum containment unit, indicate highest level of protection**
   Biosafety laboratory level BSL-2, 20 m^2. An analytical CB-deployable laboratory has been equipped with a BSL-3 glovebox.

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The objective of the research work has been in the development of detection/identification methods for biowarfare microbes and toxins. The main activity in 2009 focused on the mapping of outdoor microbial contamination and testing and evaluation air sampling methods for airborne microbes. A deployable analytical CB-laboratory has participated in Nordic military exercises. All biodefence research has been carried out with non-pathogenic strains, or otherwise harmless microbes.

   In addition, PVTT has been involved in developing of bio affinity molecules based detection kits for ricin toxins.

National Biological Defence Research and Development Programme Declaration

Description and Facilities

The Finnish Strategy to Secure Vital Functions of Society from November 2003 (and Nov. 2006) defined vital functions of Finnish society and established targets and development policies that would guide each administrative branch of the government in dealing with its strategic tasks. The strategy called for co-operation between each government sector in combating against new threats towards society. According to the Government Report on Finnish Security and Defence Policy of 2004, terrorism and epidemics caused by infectious diseases were listed as key threats affecting national security.

Based on the above resolutions The Centre for Biothreat Preparedness started operations in Helsinki in May 2005. The Centre combines Finnish scientific and laboratory knowhow on biological defence, as well as on biothreat assessment and preparedness. The Centre is actively seeking domestic and international collaboration, especially in the field of rapid detection and identification methodologies of selected biological agents. The Centre is composed of two Units; the Biological Defence Unit of the Finnish Defence Forces, and the Biological Threat Unit of the National Institute for Health and Welfare (THL). Scientific work is carried out in a biological safety level 3 laboratory at the THL facilities. Furthermore, the Centre works in close contact with the Epidemiologic Surveillance and Response Unit at THL. In addition, the Centre functions within the Biomedicum Helsinki Institute, where work is carried out in close contact with the CB Defence and Environmental Health Centre of the Centre for Military Medicine.

CONFIDENCE-BUILDING MEASURE B

Form B (i)

Background information on outbreaks of reportable human infectious diseases

Disease	Number of cases per year					
	2 004	2005	2006	2007	2008	2009
Tularaemia	151	62	475	403	116	405
Anthrax	0	0	-	-	-	-
Diphteria	0	0	0	0	0	0
Febris typhoides	6	8	5	10	1	4
Febris paratyphoides	9	5	5	9	11	5
Salmonellosis alia	2248	2477	2565	2732	3 129	2330
Ornithosis	0	0	-	-	-	-
Shigellosis	110	113	74	112	124	118
Nephropatia epidemica (Puumala virus infection)	1429	2402	1890	1726	3 216	1919

CONFIDENCE-BUILDING MEASURE B

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

Nothing to declare.

CONFIDENCE-BUILDING MEASURE C

Encouragement of publication of result and promotion of use of knowledge

Publications:

1. De Castro, C., Skurnik, M., Molinaro, A., Holst, O. 2009. Characterization of the specific O-polysaccharide structure and biosynthetic gene cluster of *Yersinia pseudotuberculosis* serotype O:15. Innate Immunity 15:351-359.
2. Pinta, E., Duda, K.A. Hanuszkiewicz, A., Kaczyński, Z., Lindner, B., Miller, W., Hyytiäinen, H., Vogel, C., Borowski, S., Kasperkiewicz, K., Lam, J., Radziejewska-Lebrecht, J., Skurnik, M., Holst, O. 2009. Identification and role of a 6-deoxy-4-keto-hexosamine in the lipopolysaccharide outer core of *Yersinia enterocolitica* serotype O: 3. Chemistry - a European Journal 15:9747-9754.
3. Cunneen M.M., De Castro, C., Kenyon, J., Parrilli, M., Reeves, P.R., Molinaro, A., Holst, O., Skurnik, M. 2009. The O-polysaccharide structure and biosynthetic gene cluster of *Yersinia pseudotuberculosis* serotype O:11. Carbohydrate Research 344: 1533-1540.
4. Niskanen, T., Laukkanen, R., Murros, A., Björkroth, J., Skurnik, M., Korkeala, H. and Fredriksson-Ahomaa, M. 2009. Characterisation of non-pathogenic *Yersinia pseudotuberculosis* -like strains isolated from food and environmental samples. Int. J. Food. 129:150–156.
5. Matero, P., Pasanen, T., Laukkanen, R., Tissari, P., Tarkka, E., Vaara, M., Skurnik, M. 2009. Real-time multiplex PCR assay for detection of *Yersinia pestis* and *Yersinia pseudotuberculosis.* APMIS 117: 34-44.
6. Skurnik, M., Bengoechea, J.A. 2009. Genetics and regulation of bacterial lipopolysaccharide synthesis. In *Bacterial Polysaccharides - Current Innovations and Future Trends.* Ullrich, M (ed). Caister Academic Press. pp. 27-37.
7. Skurnik, M., Rådström, P., Knutsson, R., Segerman, B., Hallanvuo, S., Lambertz, S.T., Korkeala, H., Fredriksson-Ahomaa, M. 2009. Yersinia. In *Molecular Detection of Foodborne Pathogens.* Dongyou Liu (ed). CRC Press. pp. 501-518.
8. Koskela, K.A., Matero, P., Blatny, J.M., Fykse, E.M., Olsen, J.S., Nuotio, L.O., Nikkari, S. 2009. A multi-platform real-time polymerase chain reaction detection assay for *Vibrio cholerae*. Diagn Microbiol Infect Dis. 65:339-44.
9. Makary, P., Maunula, L., Niskanen, T., Kuusi, M., Virtanen, M., Pajunen, S., Ollgren, J., Tran, M.N.N. 2009. Multiple norovirus outbreaks among workplace canteen users in Finland, July 2006. Epidemiol Infect 137:402-407.
10. Maunula, L., Klemola, P., Kauppinen, A., Söderberg, K., Nguyen, T., Pitkänen, T., Kaijalainen, S., Simonen, M.L., Miettinen, I.T., Lappalainen, M., Laine, J., Vuento, R., Kuusi, M., Roivainen, M. 2009. Enteric viruses in a large waterborne outbreak of acute gastroenteris in Finland. Food and Environmental Virology 1:31-36.
11. Pönka, A., Kotilainen, P., Rimhanen-Finne, R., Hokkanen, P., Hänninen, M.L., Kaarna, A., Meri, T., Kuusi, M. A foodborne outbreak due to Cryptosporidium parvum in Helsinki, November 2008. EuroSurveillance 2009;16.
12. Rimhanen-Finne, R., Jakava-Viljanen, M., Lyytikäinen, O., Davidkin, I., Kuusi, M. 2009. Rabies control in Finland: a 12-year experience of human and veterinary surveillance. Zoonoses and Public Health 56:496-501
13. Sihvonen, L.M., Haukka, K., Kuusi, M., Virtanen, M.J., Siitonen, A. 2009. *Yersinia enterocolitica* and *Y. enterocolitica*-like species in clinical stool specimens of humans: identification and prevalence of bio/serotypes in Finland. Eur J Clin Microbiol Infect Dis 28:757-765.

14. Sissonen, S., Pasanen, T., Salmenlinna, S., Vuopio-Varkila, J., Tarkka, E., Vaara, M., Tissari, P. 2009. Evaluation of a commercial MRSA assay when multiple MRSA strains are causing epidemics. Eur J Clin Microbiol Infect Dis 28:1271-1273.
15. Putkuri, N., Piiparinen, H., Vaheri, A. and Vapalahti, O. 2009. Detection of human orthopoxvirus infections and differentiation of smallpox virus with real-time PCR. J Med Virol. 81:146-52
16. Jääskeläinen, A.J., Moilanen, K., Bühler, S., Lappalainen, M., Vapalahti, O., Vaheri, A, Piiparinen H. 2009.Serological microarray for detection of HSV-1, HSV-2, VZV, and CMV antibodies. J Virol Methods. 160:167-71
17. Tagliapietra V, Rosà R, Hauffe HC, Laakkonen J, Voutilainen L, Vapalahti O, Vaheri A., Henttonen, H. and Rizzoli, A. 2009. Spatial and temporal dynamics of lymphocytic choriomeningitis virus in wild rodents, northern Italy. Emerg Infect Dis. 15:1019-25
18. Huhtamo, E., Putkuri, N., Kurkela, S., Manni, T., Vaheri, A. and Vapalahti, O, Uzcátegui NY. Characterization of a novel flavivirus from mosquitoes in northern europe that is related to mosquito-borne flaviviruses of the tropics. J Virol. 83:9532-40
19. Haukisalmi, V., Henttonen, H., Hardman, L., Hardman, M., Laakkonen, J., Murueva, G., Niemimaa, J., Shulunov, S. and Vapalahti, O. 2009. Review of tapeworms of rodents inthe Republic of Buryatia, with emphasis on anoplocephalid cestodes. ZooKeys 8:1-18
20. Plyusnina, A., Ferenczi, E., Racz, G. R., Nemirov, K., Lundkvist, Å.,Vaheri, A., Vapalahti, O. and Plyusnin, A. 2009. Co-circulation of three pathogenic hantaviruses: Puumala, Dobrava and Saaremaa hantaviruses in Hungary. J Med Virol. 81:2045-52.
21. Mäkelä, S., Kokkonen, L., Ala-Houhala, I., Groundstroem, K., Harmoinen, A., Huhtala, M., Hurme, M., Paakkala, A., Pörsti, I., Virtanen, V., Vaheri, A. and Mustonen, J. 2009. More than half of the patients with acute Puumala hantavirus infection have abnormal cardiac findings. Scand. J. Infect Dis. 41:57-62
22. Kallio, E.R., Begon, M., Henttonen, H., Koskela, E., Mappes, T., Vaheri, A., and Vapalahti O. 2009. Cyclic hantavirus epidemics in humans – Predicted by rodent host dynamics. Epidemics 1:101-107
23. Miettinen, M., Mäkelä, S., Ala-Houhala, I., Kööbi, T., Vaheri, A., Pasternack, A., Pörsti, I. and Mustonen, J. 2009. Tubular proteinuria and glomerular filtration 6 years after Puumala hantavirus-induced acute interstitial nephritis. Nephron Clin. Pract. 112:115-120
24. Wang, H., Strandin, T., Hepojoki, J., Lankinen, H. and Vaheri, A. 2009. Degradation and aggresome formation of the Gn tail of the apathogenic Tula hantavirus. J. Gen. Virol. 90:2995-3001
25. Heyman, P., Vaheri, A., Lundkvist, Å. and Avsic-Zupanc, T. 2009. Hantavirus infections in Europe: from virus carriers to a major public-health problem. Expert Rev. Anti Infect. Ther. 7:205-217
26. Zhang, Y.Z., Zhang, F.X., Wang, J.B., Zhao, Z.W., Li, M.H., Chen, H.X., Zou, Y. and Plyusnin A. 2009. Hantaviruses in rodents and humans, Inner Mongolia Autonomous Region, China. Emerg Infect Dis.15:885-91
27. Razzauti, M., Plyusnina, A., Sironen, T., Henttonen, H. and Plyusnin A. 2009. Analysis of Puumala hantavirus in a bank vole population in northern Finland: evidence for co-circulation of two genetic lineages and frequent reassortment between strains. J Gen Virol. 90(Pt 8):1923-31
28. Zhang, Y.Z., Dong, X., Li, X., Ma, C., Xiong, H.P., Yan, G.J., Gao, N., Jiang, D.M., Li, M.H., Li, L.P., Zou, Y. and Plyusnin, A. 2009. Seoul virus and hantavirus disease, Shenyang, People's Republic of China. Emerg Infect Dis. 15:200-6
29. Plyusnina, A., Ibrahim, I.N. and Plyusnin, A. 2009. A newly recognized hantavirus in the Asian house rat (Rattus tanezumi) in Indonesia. J Gen Virol. 90(Pt 1):205-9
30. Heyman, P., Baert, K., Plyusnina, A., Cochez, C., Lundkvist, A., Esbroeck, M.V., Goossens, E., Vandenvelde, C., Plyusnin, A. and Stuyck, J. 2009. Serological and genetic evidence for the presence of Seoul hantavirus in Rattus norvegicus in Flanders, Belgium. Scand J Infect Dis. 41:51-6

Publications in Finnish:

1. Sane, J., Kurkela, S., Vaheri, A. and Vapalahti O. Pogostantautiepidemia – joko taas? Duodecim. 125:1261-1268, 2009.
2. Das, M., Pakarinen, L., Ruotsalainen, E., Salo, E., Kotilainen, H., Zitting, S., Lehtinen, V., Kuusi, M., Davidkin, I., Leino, T., Ruutu, P. 2009) Tuhkarokkotapaus Suomessa – mitä tehdä ? (A measles case in Finland – what should you do ?). S Lääkl 64:597-600.
3. Hulkko T, Lyytikäinen O, Kuusi M, Möttönen T, Ruutu P: Tartuntataudit Suomessa 2008. Helsinki: Terveyden ja hyvinvoinnin laitos, 2009. 44 p.
4. Vartti, A-M., Mäkitie, I., Aro, A.R., Henriksson, M., Jormanainen, V., Nikkari, S. Varusmiesten käsitykset ja tietämys influenssasta palveluksen alkuvaiheessa. S Lääkl 2009; 64:3303-3310.

CONFIDENCE-BUILDING MEASURE D

Form D

Active promotion of contacts

International conferences, symposia, seminars, and other similar forums are planned for the year 2010.

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

1.1

- name of the conference: **8th Finnish Microbial Pathogenesis Day and Basic Microbiology Day 2010**
- arranging organizations: University of Helsinki, Finland
- time: November 17-18, 2010
- place: Haartman Institute, Haartmaninkatu 3, Helsinki, Finland
- main subject(s) for the conference: Microbial pathogenesis
- conditions for participation: free
- point of contact for further, information, registration: mikael.skurnik@helsinki.fi

CONFIDENCE-BUILDING MEASURE E

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	YES	NO
(b) Exports of micro-organisms* and toxins	YES	YES	YES	NO
(c) Imports of micro-organisms* and toxins	YES	YES	YES	NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Form E

Declaration of legislation, regulations and other measures

Additional information

Finland's legislation on biological weapons is based on the Biological Weapons Act 257/1975 and Decree 258/1975. Corresponding penal provisions were included in the Penal Code, chapter 11, section 7 b (Breach of the prohibition of biological weapons), with amendment 17/2003. Penal Code (39/1889) chapter 11, section 1 (War Crime), chapter 5, section 3 (Complicity in an offence) and section 6 (Abetting), chapter 34, sections 4 (Health endangerment) and 5 (Aggravated health endangerment), and chapter 34 a (Terrorist offences) are also applicable.

Exports of micro-organisms and toxins are regulated by the Act on the Control of Export of Dual-Use Goods (562/1996, as amended by Acts 891/2000, 884/2001 and 581/2003), Government Decree on the Control of Export of Dual-Use Goods (924/2000 as amended by Decree 924/2000) and EC Council Regulation 1334/2000. Corresponding penal provisions were incorporated in the Penal Code (39/1889), chapter 46, sections 1-3 by Acts 769/1990, 1522/1994 and 706/1997. Since 2003, the authority responsible for export controls of micro-organisms and toxins is the Ministry for Foreign Affairs (Export Control Unit).

Imports of micro-organisms and toxins are regulated by the Biological Weapons Act 257/1975 and Decree 258/1975. Transports of micro-organisms and toxins are also regulated by the EC Council Directives 94/55/EEC and 96/49/EEC, the Communicable Diseases Act 583/1986 (as amended), section 33; Communicable Diseases Decree 786/1986 (as amended); Act on the Transport of Dangerous Goods (719/1994 as amended) and related decrees, Act on Protecting Plant Health (702/2003), section 7, and related decrees, Act on Animal Diseases (55/1980 as amended) and related decrees, Act on Veterinary Border Control (1192/1996 as amended) and related decrees. The corresponding penal provisions are included in the Penal Code (39/1889 as amended), chapter 44, section 2 (Health protection violation), chapter 44, section 13 (Transport of dangerous substances offence) and chapter 46, section 4 (Smuggling).

CONFIDENCE-BUILDING MEASURE F

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

Nothing to declare.

CONFIDENCE-BUILDING MEASURE G

Form G

Declaration of vaccine production facilities

There are no vaccine production facilities in Finland.